Memorial Sloan Kettering Cancer Center;Cornell University
发明人:
申请号：
EP20152240.6
公开号：
EP3693026A1
申请日:
2015.05.27
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
Described herein are nanoparticle drug conjugates (NDCs), which, in certain embodiments, comprise a non-toxic, multi-modality, clinically proven silica-based nanoparticle platform with covalently attached drug molecules/moieties. The nanoparticle drug conjugates (NDCs) demonstrate imaging capability and targeting ligands which efficiently clear through the kidneys. Furthermore, the conjugates incorporate therapeutic agents for cancer detection, prevention, and/or treatment.
